scholarly journals Optimal panel of immunohistochemistry for the diagnosis of B-cell non-Hodgkin lymphoma using bone marrow biopsy: a tertiary care center study

2021 ◽  
Author(s):  
Nisha Marwah ◽  
Manali Satiza ◽  
Niti Dalal ◽  
Sudhir Atri ◽  
Monika Gupta ◽  
...  
Keyword(s):  
Bone Marrow ◽  
B Cell ◽  
Hodgkin Lymphoma ◽  
Bone Marrow Biopsy ◽  
Care Center ◽  
Tertiary Care ◽  
Tertiary Care Center ◽  
Non Hodgkin Lymphoma ◽  
Center Study

Non-Hodgkin lymphoma in childhood and adolescence: frequency and distribution of immunomorphological types from a tertiary care center in South India

2011 ◽  
Vol 7 (4) ◽  
pp. 318-325 ◽  
Author(s):  
Marie Therese Manipadam ◽  
Sheila Nair ◽  
Auro Viswabandya ◽  
Leni Mathew ◽  
Alok Srivastava ◽  
...  
Keyword(s):  
Hodgkin Lymphoma ◽  
South India ◽  
Care Center ◽  
Tertiary Care ◽  
Childhood And Adolescence ◽  
Tertiary Care Center ◽  
Non Hodgkin Lymphoma

scholarly journals Pattern of non-hodgkin lymphoma in a tertiary care center in Northeast India using morphology and immunohistochemistry

2019 ◽  
Vol 40 (4) ◽  
pp. 595
Author(s):  
Debanwita Mahanta ◽  
JagannathDev Sharma ◽  
Anupam Sarma ◽  
Shiraj Ahmed ◽  
Lopamudra Kakoti ◽  
...  
Keyword(s):  
Hodgkin Lymphoma ◽  
Care Center ◽  
Tertiary Care ◽  
Northeast India ◽  
Tertiary Care Center ◽  
Non Hodgkin Lymphoma

Immunophenotyping of mature B-cell non Hodgkin lymphoma involving bone marrow and peripheral blood: critical analysis and insights gained at a tertiary care cancer hospital

2009 ◽  
Vol 50 (8) ◽  
pp. 1290-1300 ◽  
Author(s):  
Sumeet Gujral ◽  
Sunita Narayan Polampalli ◽  
Y. Badrinath ◽  
Ashok Kumar ◽  
Subramanian P. G. ◽  
...  
Keyword(s):  
Bone Marrow ◽  
B Cell ◽  
Hodgkin Lymphoma ◽  
Peripheral Blood ◽  
Critical Analysis ◽  
Tertiary Care ◽  
Non Hodgkin Lymphoma ◽  
Cancer Hospital

scholarly journals Primary extranodal non-Hodgkin lymphoma: A 3-year record-based descriptive study from a tertiary care center in Southern India

2015 ◽  
Vol 58 (3) ◽  
pp. 296 ◽  
Author(s):  
Debdatta Basu ◽  
Pritinanda Mishra ◽  
Sreeya Das ◽  
Rakhee Kar ◽  
SajiniElizabeth Jacob
Keyword(s):  
Hodgkin Lymphoma ◽  
Care Center ◽  
Tertiary Care ◽  
Descriptive Study ◽  
Southern India ◽  
Tertiary Care Center ◽  
Non Hodgkin Lymphoma

scholarly journals Clinically Undetected Hodgkin Lymphoma Diagnosed Initially on Bone Marrow Biopsy: A Large Retrospective Observational Study from a Tertiary Care Center

2021 ◽  
Vol 42 (06) ◽  
pp. 554-560
Author(s):  
Navatha Vangala ◽  
Tara Roshni Paul ◽  
Shantveer G. Uppin ◽  
Megha S. Uppin ◽  
G. Sadashivudu ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Lymph Node ◽  
Hodgkin Lymphoma ◽  
Bone Marrow Biopsy ◽  
Care Center ◽  
Tertiary Care ◽  
Lymph Node Biopsy ◽  
Common Symptom ◽  
Mixed Cellularity ◽  
Loss Of Weight

Abstract Introduction Hodgkin lymphoma (HL) involving the bone marrow (BM) is relatively rare with an incidence ranging from 4% to 18%. The incidence of primary HL of marrow is 0.25%. To the best of our knowledge, the present study is the largest study on HL diagnosed initially on marrow biopsy. Objective To establish diagnostic criteria based on clinicopathological and histological features in HL diagnosed first on the marrow. Materials and Methods This was a retrospective study done from January 2012 to December 2020 that included 36 cases of HL diagnosed initially on BM. Based on the presence of large mononuclear or binucleate Reed–Sternberg (RS)-like cells in a polymorphous inflammatory background, HL was suspected and immunohistochemistry (IHC) with CD15 and CD30 was done. Correlation with subsequent lymph node biopsies was done, wherever possible. Results Fever (94.4%) was the most common symptom, followed by loss of weight (66.7%). Twenty-one cases (58.4%) had uni/bicytopenia and 15 cases (41.6%) had pancytopenia. Only one case showed suspicious mononuclear RS cells on aspirates and the rest of the cases were diagnosed on trephine biopsy alone. Trephine imprints showed variable cellularity in 13 (36%) cases. Diffuse involvement was seen in 24 cases (66.7%), and focal nodular aggregates were seen in 12 cases (33.3%). Out of 36 cases, 26 cases (19 cases on marrow and 7 cases on lymph node) were confirmed as HL with IHC. Immunophenotype of the RS cells on the marrow was CD30+/CD15+ in (6/29) (20.7%) cases, CD30+/CD15− in (7/29) (24.1%) cases and CD30−/CD15+ in (6/29) (20.7%) cases. Seven cases (26.9%) were diagnosed on subsequent lymph node biopsy as mixed cellularity HL with IHC confirmation. Marrow fibrosis was seen in 16 cases (44.4%), and granulomas were seen in 8 cases (22.2%). Conclusion In cases presenting with long-standing fever and cytopenias, HL must always be suspected, even if there are no palpable lymph nodes. Bone marrow biopsy is preferable over aspiration in such cases and IHC plays a major role in diagnosing the cases.

scholarly journals FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials

2021 ◽  
Author(s):  
Dominic Kaddu-Mulindwa ◽  
Bettina Altmann ◽  
Gerhard Held ◽  
Stephanie Angel ◽  
Stephan Stilgenbauer ◽  
...  
Keyword(s):  
Bone Marrow ◽  
B Cell ◽  
Hodgkin Lymphoma ◽  
Predictive Value ◽  
Fdg Pet ◽  
Bone Marrow Involvement ◽  
Non Hodgkin Lymphoma ◽  
Pet Ct ◽  
Fdg Pet Ct ◽  
Initial Staging

Abstract Purpose Fluorine-18 fluorodeoxyglucose positron emission tomography combined with computed tomography (FDG PET/CT) is the standard for staging aggressive non-Hodgkin lymphoma (NHL). Limited data from prospective studies is available to determine whether initial staging by FDG PET/CT provides treatment-relevant information of bone marrow (BM) involvement (BMI) and thus could spare BM biopsy (BMB). Methods Patients from PETAL (NCT00554164) and OPTIMAL>60 (NCT01478542) with aggressive B-cell NHL initially staged by FDG PET/CT and BMB were included in this pooled analysis. The reference standard to confirm BMI included a positive BMB and/or FDG PET/CT confirmed by targeted biopsy, complementary imaging (CT or magnetic resonance imaging), or concurrent disappearance of focal FDG-avid BM lesions with other lymphoma manifestations during immunochemotherapy. Results Among 930 patients, BMI was detected by BMB in 85 (prevalence 9%) and by FDG PET/CT in 185 (20%) cases, for a total of 221 cases (24%). All 185 PET-positive cases were true positive, and 709 of 745 PET-negative cases were true negative. For BMB and FDG PET/CT, sensitivity was 38% (95% confidence interval [CI]: 32–45%) and 84% (CI: 78–88%), specificity 100% (CI: 99–100%) and 100% (CI: 99–100%), positive predictive value 100% (CI: 96–100%) and 100% (CI: 98–100%), and negative predictive value 84% (CI: 81–86%) and 95% (CI: 93–97%), respectively. In all of the 36 PET-negative cases with confirmed BMI patients had other adverse factors according to IPI that precluded a change of standard treatment. Thus, the BMB would not have influenced the patient management. Conclusion In patients with aggressive B-cell NHL, routine BMB provides no critical staging information compared to FDG PET/CT and could therefore be omitted. Trial registration NCT00554164 and NCT01478542

scholarly journals The utility of cytology in the diagnosis of adenocarcinoma lung: A tertiary care center study

2015 ◽  
Vol 32 (3) ◽  
pp. 159 ◽  
Author(s):  
Saumya Shukla ◽  
KiranPreet Malhotra ◽  
Nuzhat Husain ◽  
Anurag Gupta ◽  
Nidhi Anand
Keyword(s):  
Care Center ◽  
Tertiary Care ◽  
Tertiary Care Center ◽  
Center Study
Sign in / Sign up

Export Citation Format

Share Document